NeuroXT NEXT-Cue FDA clearance gives clinicians a new AI tool for one narrow question: whether a patient with mild cognitive impairment may progress to Alzheimer’s dementia within five years. The Seoul-based company announced on 20 October 2026 that NEXT-Cue, an AI-based Software as a Medical Device, received FDA 510(k) clearance as a Class II device. The software combines brain MRI images with demographic information and cognitive-assessment data to give additional information for clinical assessment and care planning. It is a prognostic support tool, not a diagnostic system, a cure or a treatment.
NeuroXT NEXT-Cue FDA clearance: key takeaways
- NEXT-Cue received 510(k) clearance as a Class II Software as a Medical Device, per NeuroXT’s announcement.
- It supports clinicians assessing patients with mild cognitive impairment for progression to Alzheimer’s dementia within five years.
- Inputs are brain MRI images, demographic information and cognitive-assessment data.
- It is not an autonomous diagnostic and not a treatment for Alzheimer’s disease.
- The announcement gives no performance figures, so accuracy cannot be judged from it.
What the NeuroXT NEXT-Cue FDA clearance covers
The indication, as described by the company, is to support clinicians in assessing patients with mild cognitive impairment who are being evaluated for progression to Alzheimer’s dementia within five years. The output is supplementary information to support clinical assessment and individualised patient management planning. Chief Executive Joon-Kyung Seong called the clearance an important milestone in the company’s entry into the U.S. healthcare market. NeuroXT describes itself as a medical AI company that develops AI-based imaging biomarkers for Alzheimer’s disease, mainly using MRI. More on the company is on the NeuroXT website.
What information NEXT-Cue uses
According to the announcement, the software draws on three kinds of input: brain MRI images, demographic information and cognitive-assessment data. It then provides information about the risk of progression over a five-year horizon. The release does not describe the underlying model, the training data, how the three inputs are weighted, or the format of the output, so we do not speculate. The NEXT-Cue product information page is the place to look for such details when they are published.
Risk assessment is not diagnosis
General background: mild cognitive impairment describes a noticeable decline in memory or thinking that does not yet prevent a person from managing daily life. Some people with it later develop dementia, while others remain stable or improve, so doctors want ways to estimate who is at higher risk. A prognostic tool estimates what may happen over time, which is different from diagnosing a condition that is present now. The announcement describes NEXT-Cue as supporting clinical assessment, and clinicians would still weigh its output alongside examination, history and other tests.
Why prognosis matters in the memory clinic
This section is our general framing and not a company claim. A patient with mild cognitive impairment and their family often want to know what to expect, and the answer can shape decisions about follow-up visits, planning for the future, lifestyle measures and whether to be considered for new treatments or research studies. A reliable estimate of five-year risk could help clinicians decide who needs closer monitoring. An unreliable one could cause needless worry or false reassurance, which is why the validation data that the announcement omits matter so much.
What the NeuroXT NEXT-Cue FDA clearance means
This section is general background. In U.S. device regulation, a 510(k) clearance means the FDA has determined that a device is substantially equivalent to a legally marketed device. Class II devices are those for which general controls alone are not considered enough and special controls may apply. Clearance is not the same as proof that a device improves patient outcomes, and the release does not say what evidence supported this clearance. General regulator information is on the FDA medical devices pages.
What the NeuroXT NEXT-Cue FDA clearance announcement omits
The release reports no validation or performance metrics and states no limitations, contraindications or warnings. It does not say how accurate the five-year risk estimates are, in which populations the software was tested, or how it compares with a clinician’s unaided judgement. Those are the questions clinicians and hospital buyers will ask first, and we flag them so readers do not assume that clearance answers them.
Availability after the NeuroXT NEXT-Cue FDA clearance
In the United States, the company plans to begin real-world clinical use at leading healthcare institutions and to advance commercialisation and adoption. In South Korea, it is pursuing authorisation from the Ministry of Food and Drug Safety and plans to begin commercialisation early next year. No pricing, customers or launch dates were given for the U.S.
Questions clinicians may ask about NeuroXT NEXT-Cue FDA clearance
This list is our suggestion and not a company statement. How was the software validated, and in what patient groups? How should a risk estimate be communicated to a patient and family? How does it fit with other tools used to assess cognitive decline? What happens if the MRI is of lower quality, or if cognitive-assessment data are incomplete? Answers to these will decide how much weight clinicians give the output.
What is not disclosed on NeuroXT NEXT-Cue FDA clearance
- Performance figures and validation population.
- The model’s design and how inputs are combined.
- Pricing and U.S. launch timing.
- Limitations and contraindications.
Risks and caveats on NEXT-Cue claims
- Descriptions come from the company announcement.
- Clearance does not prove clinical benefit.
- General explanations of 510(k) and mild cognitive impairment are background.
- This is news reporting, not medical advice.
In our assessment, the NeuroXT NEXT-Cue FDA clearance is a notable step for AI in neurology, but its value depends on published performance data and on how clinicians use a risk estimate in practice, and not on the clearance itself. See also Happy Ring Gets FDA Clearance for Cuffless Blood Pressure. More in our healthcare IT coverage.
What to watch next on NeuroXT NEXT-Cue FDA clearance
- Publication of validation and performance data.
- First U.S. institutions to use the software.
- The South Korean authorisation decision.
Frequently asked questions
What is NEXT-Cue?
An AI-based Software as a Medical Device that supports clinicians assessing five-year progression risk to Alzheimer’s dementia in patients with mild cognitive impairment.
Does it diagnose Alzheimer’s disease?
No. It is a prognostic support tool, and it is not a cure or a treatment.
What data does it use?
Brain MRI images, demographic information and cognitive-assessment data.
How we reported this: we relied on NeuroXT’s announcement of 20 October 2026 and public regulator pages. General background is labelled. Last updated: 20 October 2026. This article is news reporting and not medical advice.